Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr;39(4):972-975.
doi: 10.1038/s41375-025-02539-0. Epub 2025 Feb 27.

CD34+CD38- leukemia stem cells predict clinical outcomes in acute myeloid leukemia patients treated non-intensively with hypomethylating agents

Tom Reuvekamp  1   2   3 , Lok Lam Ngai  1   2 , Daphne den Hartog  1   2 , Jannemieke Carbaat-Ham  1   2 , Mona M H E Fayed  1   2 , Willemijn J Scholten  1   2 , Tim R Mocking  1   2 , Dana A Chitu  4   5 , Thomas Pabst  6 , Saskia K Klein  7   8 , Georg Stussi  9 , Laimonas Griskevicius  10 , Dimitri Breems  11 , Danielle van Lammeren-Venema  12 , Rinske Boersma  13 , Gert J Ossenkoppele  1   2 , Arjan A van de Loosdrecht  1   2 , Costa Bachas  1   2 , Gerwin Huls  7 , David C de Leeuw  1   2 , Jacqueline Cloos  14   15
Affiliations

CD34+CD38- leukemia stem cells predict clinical outcomes in acute myeloid leukemia patients treated non-intensively with hypomethylating agents

Tom Reuvekamp et al. Leukemia. 2025 Apr.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests: LG holds membership on an entity’s board of directors or advisory committees for Miltenyi Biomedicine. AAvdL has received honoraria from Amgen, Novartis, Celgene/BMS, and Takeda and has received research funding from Alexion. DCdL participates in the sponsored speaker’s bureau of Servier, Roche and AbbVie; is part of the scientific advisory board of Takeda and Servier. GJO serves as a consultant for Novartis, Pfizer Inc, Celgene, Janssen, AGIOS, Amgen, Gilead, Astellas, Roche, Jazz Pharmaceuticals, and Merus; has received honoraria from Novartis, Celgene, AGIOS, Gilead, and Astellas; received research funding from Novartis; and holds membership on an entity’s board of directors for Roche. JC receives royalties from Navigate and BD Biosciences; participated in the sponsored speaker’s bureau of Astellas; and has received research funding from Takeda, DC-one, Genentech, Janssen, Novartis, and Merus. The remaining authors declare no competing financial interests. Ethics approval and consent to participate: Patients signed informed consent and the study was conducted according to the declaration of Helsinki. The study was approved by the medical ethics committee of the University Medical Center Groningen (number: 2015.550).

Figures

Fig. 1
Fig. 1. Prognostic relevance of LSC status at diagnosis, using a cutoff of 0.01% of WBC and after three cycles of therapy, using a cutoff of 0.001% of WBC.
A Overall survival (OS) based on LSC status at diagnosis. B Cumulative incidence of relapse (CIR) based on LSC status at diagnosis from the time of first CR. C Multivariable Cox regression of the overall survival from diagnosis for LSC status at diagnosis. D Overall survival based on LSC status after three cycles from the time of sampling. E Cumulative incidence of relapse for patients reaching CR/CRi/MLFS from time of sampling based on LSC status after three cycles F Multivariable Cox regression for overall survival for LSC status after three cycles (C3).
Fig. 2
Fig. 2. LSC kinetics between diagnosis (DN) and third cycle (C3) and until relapse.
A Proportion of patients categorized as CD34neg (green), LSCneg (dark blue), LSCpos (red), no material or unsuitable sample (orange) and did not reach the third cycle (light blue) at diagnosis (DN) or after three cycles of HMA treatment (C3). B LSC percentages at diagnosis and after three cycles for descending, stable, and ascending trajectories, defined as log increase, log decrease or no log difference between diagnostic and follow-up samples. C Individual LSC kinetics of three representative patients that relapsed with an LSCneg result after three cycles (other patients can be found in Fig. S11). Dark green line represents LSC cutoff after three cycles (0.001%).
See this image and copyright information in PMC

References

    1. Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345–77. - PubMed
    1. Jahn E, Saadati M, Fenaux P, Gobbi M, Roboz GJ, Bullinger L, et al. Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients. Leukemia. 2023;37:2187–96. - PMC - PubMed
    1. Döhner H, DiNardo CD, Appelbaum F, Craddock C, Dombret H, Ebert BL et al. Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations. Blood. 2024;144:blood.2024025409. - PubMed
    1. Short NJ, Zhou S, Fu C, Berry DA, Walter RB, Freeman SD, et al. Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-analysis. JAMA Oncol. 2020;6:1890–9. - PMC - PubMed
    1. Huls G, Chitu DA, Pabst T, Klein SK, Stussi G, Griskevicius L, et al. Ibrutinib added to 10-day decitabine for older patients with AML and higher-risk MDS. Blood Adv. 2020;4:4267–77. - PMC - PubMed